All News
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA
Bella Mehta bella_mehta ( View Tweet)
Adherence to TNFi follows different trajectories
Cluster 1: “moderate then high” 51%
Cluster 2: “moderate then low” 20%
Cluster 3: “low adherence, to discontinuation” 18%
Cluster 4: “low then high adherence” 11%
Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
Aurelie Najm AurelieRheumo ( View Tweet)
@eular_org recommendations session #EULAR2023 - and the first recommendation is one I’m so glad is up front:
Adult Onset Still’s Disease (AOSD) and Systemic JIA (sJIA) are the same disease.
If anything, it’s the really young sJIA (<18 months old) which is different @RheumNow https://t.co/OCDeeNtNoR
David Liew drdavidliew ( View Tweet)
@eular_org recommendation for AOSD/sJIA:
An IL-1 or IL-6 inhibitor should be initiated as early as possible when the diagnosis is established
#EULAR2023 @RheumNow https://t.co/xNUdpGDxb9
David Liew drdavidliew ( View Tweet)
#EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimumab for non-renal lupus. Post-hoc analysis of 5 BEL Non-LN RCTs showed 8% had de novo LN. Risk increased in Asians but lowered with low dose BEL or s/c form @RheumNow https://t.co/GqAr3tppWh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
One new overarching principle for @eular_org PsA recommendations:
“The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile”
Wonder what triggered that
#EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za
David Liew drdavidliew ( View Tweet)
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan synovialjoints ( View Tweet)
New 2023 @eular_org SLE recommendations
Key changes, in response to evidence:
- more caution re: steroids
- biologics earlier
- combo therapy (BEL or CNI/VCS) considered for lupus nephritis
#EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
David Liew drdavidliew ( View Tweet)
Key points from #EULAR2023 on how to manage SLE
@RheumNow https://t.co/vJy7Cg7w8N
David Liew drdavidliew ( View Tweet)
Late Breaker - EULAR 2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009, #EULAR2023 @RheumNow https://t.co/ya41nJG6qK
Dr. Antoni Chan synovialjoints ( View Tweet)
#ClinicalPearl This is cool - think of SGLT2 for #lupus #nephritis? presented at #SLE recommendations @RheumNow #EULAR2023 @eular_org https://t.co/8mbNt2n64v
Janet Pope Janetbirdope ( View Tweet)
#SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends @RheumNow #EULAR2023 https://t.co/Ylnnl3pHOK
Janet Pope Janetbirdope ( View Tweet)
Late Breaker - Cardiorespiratory fitness increased in patients with IJD after 12 weeks of supervised
HIIT and effect maintained at 6 months. No significant differences in pain and fatigue vs control. HIIT is a viable intervention Norden K Abst#LB0007 #EULAR2023 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Diagnostic delay in #lupus is really prevalent!
#EULAR2023 @RheumNow
20% with new lupus diagnosis are hospitalized!
20% diagnosis is delayed for more than 3 months! https://t.co/1vCcezBrQS
Bella Mehta bella_mehta ( View Tweet)
2023 @eular_org recommendations for LVV imaging
interestingly, the key changes vs 2018 are about PET/CT:
- can consider PET/CT for cranial GCA diagnosis
- PET/CT (alt MRI) can be used for monitoring - more for when you lose ESR/CRP because of IL-6i
#EULAR2023 @RheumNow https://t.co/2DC37CM6gA
David Liew drdavidliew ( View Tweet)
Meds in #lupus at #EULAR2023 recs
- HCQ first line therapy. Target dose remains the same. Some discussion on monitoring levels if possible
- MAIN CHANGE - Glucocorticoids to be minimized (only use for bridging). Nephrologists more so in favor of steroid free remission @RheumNow https://t.co/d8WnUOgrwq
Bella Mehta bella_mehta ( View Tweet)
Scleroderma therapeutics: we’re actually getting some choices!
Christian Dejaco #EULAR2023 @RheumNow https://t.co/sW2FBY0RqS
David Liew drdavidliew ( View Tweet)
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
Bella Mehta bella_mehta ( View Tweet)
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
Bella Mehta bella_mehta ( View Tweet)